Inflammatory bowel disease (IBD), which includes ulcerative colitis (UC) and Crohn’s disease (CD), results from a complex etiology of genetic predisposition, changes in the mucosal immune system, and environmental factors, which lead to a variety of different phenotypes in both UC and CD. Because of the myriad and potentially serious limitations to current therapies and our increasing understanding of IBD pathophysiologic mechanisms, there is great interest in the development of new agents to address potential therapeutic targets and to better use laboratory information to tailor therapy. This program presents some the key abstracts presented at Digestive Disease Week (DDW) 2015 by 3 renowned faculty in IBD. They present the data from these abstracts and discuss the potential relevance of the findings in the modern clinical management of patients with IBD.

The goal of this activity is to provide gastroenterologists and other primary healthcare providers who treat and manage patients with IBD with a review of scientific highlights from the DDW Annual meeting, to translate evidence on current and emerging treatment options for patients with IBD into practice.

This activity is designed for gastroenterologists and other primary providers of care for patients with IBD. No prerequisites required.

After completing this activity, the participant will demonstrate the ability to:
  • IDENTIFY novel laboratory methods under investigation to better understand disease course and response to treatment.
  • RECOGNIZE recent advances in experimental therapeutic approaches to IBD based on improved understanding of IBD pathophysiology.
  • DESCRIBE treatment approaches under investigation for patients with refractory moderate to severe IBD.

Gary R. Lichtenstein, MD (Course Director)
Professor of Medicine
Raymond and Ruth Perelman School of Medicine
of the University of Pennsylvania
Director, Center for Inflammatory Bowel Disease
Department of Medicine
Division of Gastroenterology
Philadelphia, Pennsylvania

David T. Rubin, MD, AGAF
The Joseph B. Kirsner Professor of Medicine
Chief, Section of Gastroenterology, Hepatology, and Nutrition
Co-Director, Digestive Diseases Center
The University of Chicago Medicine
Chicago, Illinois

Asher A. Kornbluth, MD
Clinical Professor of Medicine
Clinical Research Director, the Sanford J. Grossman Integrative Center for the Study of IBD
The Inflammatory Bowel Disease Center
The Henry D. Janowitz Division of Gastroenterology
Mount Sinai School of Medicine
New York, New York

Release date: December 10, 2015   Expiration date: December 10, 2017.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the AGA Institute and ASiM. The AGA Institute is accredited by the ACCME to provide continuing medical education for physicians.

The AGA Institute designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

In accordance with the ACCME’s Standards for Commercial Support of Continuing Medical Education, all faculty and planning partners must disclose any financial relationship(s) or other relationship(s) held within the past 12 months. The AGA Institute implements a mechanism to identify and resolve all conflicts of interest prior to delivering the educational activity to learners.

Dr Lichtenstein reports receiving grants/research support from and serving as a consultant for Ferring Pharmaceuticals, Janssen Biotech, Inc, Prometheus Laboratories Inc, Salix Pharmaceuticals, Inc/Santarus, Inc, Shire plc, UCB, Inc, and Warner Chilcott plc; receiving honoraria from American Regent, Inc, Clinical Advances in Gastroenterology, Gastro-Hep Communications, Inc, Ironwood Pharmaceuticals, Inc, Luitpold Pharmaceuticals, Inc, McMahon Group, Springer Science+Business Media, and; and for serving as a consultant for Abbott, AbbVie Inc, ACTAVIS, Alaven Pharmaceutical LLC/Meda Pharmaceuticals Inc, American Regent Inc, Ferring Pharmaceuticals, Hospira Inc, Luitpold Pharmaceuticals Inc, Pfizer Inc, and Takeda Pharmaceutical Company Limited.

Dr Moayyedi reports serving on a speakers’ bureau for ACTAVIS and Shire plc.

Dr Rubin reports receiving grants/research support from and serving as a consultant for AbbVie Inc, Janssen Biotech, Inc, Prometheus Laboratories Inc, Shire plc, Takeda Pharmaceutical Company Limited, and UCB, Inc; receiving grants/research support from Warner Chilcott plc; and serving as a consultant for Emmi Solutions, LLC, Genentech Inc, Salix Pharmaceuticals Inc/Santarus Inc, and Telsar Pharma Inc.

The following faculty members have disclosed that their presentation will reference unlabeled/unapproved use of drugs or products:

Dr Lichtenstein–Azathioprine, 6-mercaptopurine for treating patients with Crohn’s Disease and ulcerative colitis; methotrexate for treating patients with Crohn’s Disease and ulcerative colitis.

There is no fee for this educational activity.


Hot Topics in IBD
Gary R. Lichtenstein, MD, David T. Rubin, MD, AGAF, and Asher A. Kornbluth, MD


Submit a case to review at meeting:

procced to pretest

MyCMESite is published by ASiM CE, LLC, d/b/a ASiM 166 W. Main Street, Somerville, NJ 08876. (908) 253-9001. Copyright ©2017 by ASiM CE, LLC. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from the publisher. ASiM is a registered trademark of ASiM CE LLC. Contact Us